(Press-News.org) PHILADELPHIA--Real-word evidence is suggesting, for the first time, the most beneficial treatment courses that could help extend the lives of patients with metastatic non-small cell lung cancer, according to research from the Abramson Cancer Center at the University of Pennsylvania.
In a new study published online today in JAMA Oncology, researchers show that patients harboring a KRAS gene mutation with high levels of PDL-1 lived longer when treated with immunotherapy alone, compared to patients without this mutation. This survival difference by KRAS status was not seen, however, in patients treated with both chemotherapy and immunotherapy, suggesting combination therapy for patients without the mutation may be preferred.
The new findings, based off an analysis of the Flatiron Health database that includes aggregated, de-identified data from the electronic health records of more than 65,000 patients with advanced non-small cell lung cancer, provide much-needed guidance to treat a disease that has a five-year survival of just 35 percent.
"This is a prime example of how real-world data can complement clinical trial data to help inform decision making between patients and their oncologists," said senior author Ronac Mamtani, MD, an assistant professor of Hematology-Oncology in the Perelman School of Medicine at the University of Pennsylvania.
Oncologists have several options to treat patients with metastatic non-small cell lung cancer and high levels of the immune biomarker known as PD-L1, including checkpoint inhibitors such as pembrolizumab or atezolizumab, which block different proteins, like PD-1 and PDL-1, that keep T cells from killing cancer cells. The therapy has changed the treatment landscape for many cancers, including lung, and is often paired with chemotherapies; however, which treatments or combination of treatments are best suited for patients with the KRAS mutation has been unclear.
"Many of the treatment decisions for these patients are imperfect and non-data driven, with no biomarkers to help guide them," said first author Lova Sun, MD, a fellow in the division of Hematology-Oncology in the Perelman School of Medicine.. "This study shows us an important piece of the molecular data, which is something the field hasn't had."
In the exploratory analysis of four years of clinical data that included more than 1,100 patients, the researchers found that about half of the patients with PDL-1 levels higher than 50 percent tested positive for a KRAS mutation.
Patients with KRAS mutation and treated with a checkpoint inhibitor alone had superior survival compared to patients without the mutation: 21.1 vs 13.6 months. Among patients treated with chemo and immunotherapy, however, there was no significant survival difference between patients with or without the mutation. Also, patients without the mutation treated with just immunotherapy had worse survival than those treated with chemo and immunotherapy (13.6 vs 19.3 months), although the difference was not statistically significant.
These findings are applicable to a large subset of lung cancer patients, the researchers said.
"A third of patients with non-small cell lung cancer have high PD-L1, and of those patients, many have a mutation in KRAS," said co-senior author Charu Aggarwal, MD, MPH, the Leslye M. Heisler Associate Professor for Lung Cancer Excellence in Penn's Perelman School of Medicine. "There will be clinical implications for a large portion of patients with advanced lung cancer, as we learn more about this mutation and how other mutations may play a role in response."
Penn co-authors on the study Miles Tan, Roger B Cohen, and Corey J. Langer.
INFORMATION:
Inspired by the workings of a bat's ear, Rolf Mueller, a professor of mechanical engineering at Virginia Tech, has created bio-inspired technology that determines the location of a sound's origin.
Video: https://www.youtube.com/watch?v=buFM5KkAnEo
Mueller's development works from a simpler and more accurate model of sound location than previous approaches, which have traditionally been modeled after the human ear. His work marks the first new insight for determining sound location in 50 years.
The findings were published in Nature Machine Intelligence ...
There is no cheaper way to generate electricity today than with the sun. Power plants are currently being built in sunny locations that will supply solar electricity for less than two cents per kilowatt hour. Solar cells available on the market based on crystalline silicon make this possible with efficiencies of up to 23 percent. Therefore they hold a global market share of around 95 percent. With even higher efficiencies of more than 26 percent, costs could fall further. An international working group led by photovoltaics researchers from Forschungszentrum Jülich ...
More than 20 years after the launch of a landmark clinical trial, follow-up examinations and analyses found that not all patients with elevated eye pressure need pressure-lowering treatment to prevent vision loss from glaucoma.
When the study was launched, it was universally accepted that all patients with elevated eye pressure should be given medication to lower that pressure. The Ocular Hypertension Treatment Study -- funded by the National Eye Institute of the National Institutes of Health (NIH) and led by researchers at Washington University School of Medicine ...
Prime editing (PE), a "search-and-replace" CRISPR-based genome editing technique, has great potential for gene therapy and agriculture. It can introduce desired base conversions, deletions, insertions, and combination edits into target genomic sites. Prime editors have been successfully applied in animals and plants, but their off-target effects, which can be a major hindrance to real-life application, have not been thoroughly evaluated until now.
Prof. GAO Caixia from the Institute of Genetics and Developmental Biology (IGDB) of the Chinese Academy of Sciences (CAS) and her research team recently performed a comprehensive and genome-wide analysis of the off-target effects of PEs in rice plants.
Off-target ...
It is an old-standing theory in evolutionary ecology: animal species on islands have the tendency to become either giants or dwarfs in comparison to mainland relatives. Since its formulation in the 1960s, however, the 'island rule' has been severely debated by scientists. In a new publication in Nature Ecology and Evolution on April 15, researchers solved this debate by analysing thousands of vertebrate species. They show that the island rule effects are widespread in mammals, birds and reptiles, but less evident in amphibians.
Dwarf hippos and elephants in the Mediterranean islands are examples of large ...
Using a new single-cell technique, WEHI researchers have uncovered a way to understand the programming behind how stem cells make particular cell types.
The research uncovered 30 new genes that program stem cells to make the dendritic cells that kick-start the immune response.
By uncovering this process, the researchers hope they will be able to find new immunotherapy treatments for cancer, and plan to expand this technique in other areas such as discovering new drug targets in tumour initiation.
At a glance
WEHI researchers have developed a new single cell method to understand the programming behind what causes stem cells to make ...
El Niño-Southern Oscillation (ENSO) is an irregular periodic variation in winds and sea surface temperatures (SSTs) over the tropical eastern Pacific Ocean. It may lead to extreme weather events across the globe due to its ability to change global atmospheric circulation. Thus, determining how ENSO responds to greenhouse warming is crucial in climate science.
However, quantifying and understanding ENSO-related changes in a warmer climate remains challenging due to the complexity of air-sea feedbacks in the tropical Pacific Ocean and to model bias.
An international team of scientists ...
Antibodies are not only produced by our immune cells to fight viruses and other pathogens in the body. For a few decades now, medicine has also been using antibodies produced by biotechnology as drugs. This is because antibodies are extremely good at binding specifically to molecular structures according to the lock-and-key principle. Their use ranges from oncology to the treatment of autoimmune diseases and neurodegenerative conditions.
However, developing such antibody drugs is anything but simple. The basic requirement is for an antibody to bind to its target molecule in an optimal way. At the same time, an antibody drug must fulfil a host of additional criteria. For example, it should not trigger ...
COVID-19 has been associated with increases in opioid overdose deaths, which may be in part because the pandemic limited access to buprenorphine, a treatment used for opioid dependency, according to a new study led by Princeton University researchers.
The researchers found that Americans who were already taking opioids did not experience disruptions in their supply. Patients who were not previously taking opioids for pain management were less likely to receive a new prescription in the first months of the pandemic, but prescriptions for new patients soon bounced back to previous levels.
At the same time, fewer ...
A number of SARS-CoV-2 variants have emerged from immunocompromised hosts, research has identified. It is thought that variants of concern - including B.1.1.7, a variant first identified in Kent - were a result of long-term infection in people with a weakened immune system.
Persistent infections in immunocompromised people could cause the virus to mutate more frequently because the person's immune system cannot clear the virus as quickly as the immune system of a healthy person.
Authors Professor Wendy Barclay, Dr Thomas Peacock, Professor Julian Hiscox and Rebekah Penrice-Randal explain the importance of monitoring genetic changes in SARS-CoV-2 for future control of the virus: ...
